Agree. And positive readout figures for PH and Angelman trials may suddenly make 50/sh look a little cheap. Let's not forget the detailed numbers that have been run by some learned folk on our "superior drug"* in terms of potential sales and profits..
If NNZ-2591 proves effective (and PMS trail suggest it will be), and gets market penetration of a Daybue calibre, well, not only will patients and families benefit enormously, but someone is going to make a very, very large pile of money.
*JP's words, not mine.
GLA.
Agree. And positive readout figures for PH and Angelman trials...
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.83 |
Change
-0.270(1.34%) |
Mkt cap ! $2.569B | |||
| Open | High | Low | Value | Volume |
| $20.17 | $20.17 | $19.66 | $797.9K | 40.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11 | $19.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.86 | 196 | 5 |
View Market Depth
| Last trade - 10.42am 03/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |